The Anna-Maria Kellen Clinical Accelerator is a unique academia-industry partnership model and drug development incubator designed to help organize and de-risk clinical study of next-generation combination cancer immunotherapies.
The program is led by a global network of 80 of the field’s leading clinician-scientists who work collaboratively to identify potentially transformative treatments and to design cutting-edge clinical trials and correlative research efforts to test them. Prioritized studies are launched with a comprehensive set of nonprofit resources and a unique IP model that facilitates access to top drugs from different companies.
Clinical Accelerator currently has more than 15 significant industry and nonprofit partners. The model is powered by a nonprofit venture capital fund that enables it to achieve significant leverage via co-investments, and is structured to become self-sustaining over time via returns on investment back to the charity as supported drugs become successful.
At current, the program invests approximately $20 to $30 million in innovative clinical trials each year. It’s a win-win-win model: Cancer patients gain access to promising new treatment options; Scientists gain extraordinary clinical research and publication opportunities; and Company partners gain valuable investment of nonprofit resources and expertise into their drugs.